Recent events
Recent events tied to this brand in public sources.
Back to profile20 entries
2026
Novo Nordisk announces CFO Karsten Munk Knudsen will leave
Reuters reported that Novo Nordisk CFO Karsten Munk Knudsen is to leave the company.
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
2026
Novo Nordisk reports new CagriSema study data on reduced food noise and organ and bone health improvements
Novo Nordisk released new data this week from a yearlong functional magnetic resonance imaging study showing that CagriSema, its combination of cagrilintide and semaglutide, reduced food noise (persistent thoughts about food) and showed improvements to organ and bone health in people with obesity or who were overweight. Novo said CagriSema changed how the brain reacted to tempting, high-calorie foods in areas linked to cravings, pleasure and self-control.
2026
Novo Nordisk to pay up to $2.6 billion to Hengrui for rights to weight-loss pill
Reuters reported that Novo Nordisk is to pay up to $2.6 billion to China's Hengrui Pharma for rights to a weight-loss pill.
2026
Novo Nordisk enters €1.17 billion deal with Nanexa for injection technology
Novo Nordisk entered a €1.17 billion deal with Nanexa covering injection technology, and Nanexa's shares soared on the news.
2026
Novo Nordisk strikes licensing deal with a Swedish company
MarketWatch reported that Novo Nordisk has struck a licensing deal with a Swedish company, and that news of the deal sent the Swedish company's stock soaring. The report notes the deal came after Novo's capital-markets day was received poorly. The Swedish counterparty is not named in the available source text, and no deal date is stated in the headline.
2026
Nanexa signs $1.33 billion global licensing deal with Novo Nordisk for PharmaShell technology
Swedish drug-delivery company Nanexa announced a global licensing agreement with Novo Nordisk, granting the maker of Wegovy and Ozempic exclusive rights for up to five development programs to use Nanexa's PharmaShell technology, an ultra-thin inorganic coating on drug particles that controls release over time, for long-acting injectable drugs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Nanexa is eligible for an upfront payment of around $700 million, milestone payments for development and regulatory achievements, and low single-digit royalties on future product sales, in a deal reported at $1.33 billion. Nanexa shares surged more than 150% at Friday's open in Stockholm before paring gains.
2026
Novo Nordisk CEO says company open to direct NYSE share listing
Novo Nordisk's chief executive said the company is open to a direct listing of its shares on the New York Stock Exchange.
2026
Novo Nordisk lays out growth strategy and pipeline targets at Capital Markets Day
At its Capital Markets Day on Monday, Novo Nordisk laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, promising a pipeline of potential blockbuster products and diversification beyond obesity and diabetes. Targets included launching more than five potential multi-blockbuster drugs by 2030, more than 150 billion Danish kroner (about $23 billion) in pipeline sales by 2035, at least five Phase 3 programs in obesity and diabetes plus five across other therapeutic areas, and a tenfold increase in patients on its GLP-1 drugs by 2030. Investors sold off Novo's stock after the presentation, with growth targets matching industry averages rather than outpacing them.
2026
Novo Nordisk launches once-daily Wegovy weight-loss pill in the US
Novo Nordisk launched the once-daily pill version of its weight-loss drug Wegovy in the United States on Monday, following FDA approval in December 2025. The pill is priced at $199-$299 per month and will be sold through US pharmacies including Costco and CVS and telehealth providers such as Ro, LifeMD, WeightWatchers, GoodRx and NovoCare Pharmacy.
2022
Novo Nordisk launches oral semaglutide in India
Novo Nordisk announced the launch of oral semaglutide in India for the treatment of type 2 diabetes. The source says the pill had been approved by India’s Drugs Controller General in 2020.
2021
Novo Nordisk and Hainan Boao Lecheng authority sign strategic cooperation memorandum
Novo Nordisk and the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administrative Bureau signed a strategic cooperation memorandum during the China International Import Expo. The cooperation focuses on chronic diseases, including the introduction of innovative medicines, physician training, market preparation and chronic disease management.
2021
Novo Nordisk recalls certain product samples
Novo Nordisk voluntarily recalled 1,468 samples of Levemir, Tresiba, Fiasp, NovoLog and Xultophy to the consumer level because they had been stored below the required temperature. The recall affected product samples, not products broadly distributed to pharmacies or mail-order services; the company said it had received no reports of serious adverse events or injuries related to the recall.
2021
Novo Nordisk appoints Romania corporate affairs director
Novo Nordisk appointed Cristina Popescu as its corporate affairs director for Romania, with the appointment starting in January 2021.
2020
Novo Nordisk raises 2020 sales and operating profit outlook
Novo Nordisk announced preliminary third-quarter 2020 sales and operating profit results and raised its 2020 sales and operating profit outlook at constant exchange rates.
2020
Novo Nordisk acquisition of Corvidia Therapeutics announced
Sofinnova Partners announced the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1 billion, including an upfront payment of $725 million. The source reports the sale announcement, not completion of the acquisition.
2020
FDA approves Fiasp for children aged 2 and older
The FDA approved Fiasp, an insulin aspart injection from Novo Nordisk, for treating diabetes in children as young as 2 years old.
2020
Novo Nordisk appoints Vikrant Shrotriya to lead its India business
Novo Nordisk appointed Vikrant Shrotriya as Managing Director and Corporate Vice President for its India business. He will be based in Bengaluru.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
Dicerna and Novo Nordisk partner on liver-related diseases
Dicerna Pharmaceuticals and Novo Nordisk partnered to discover and develop treatments for liver-related cardio-metabolic diseases, using Dicerna’s GalXC RNAi technology platform to explore more than 30 liver cell targets.